Evidence map›Paper›PMID 40938549›Full record

ArticleCardiovascular drugs and therapy2026

Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.

Shriya Chunduri, Ghassan Bidaoui, Mohammad H Hussein, Milee Patel, Ahmed Abdelmaksoud, Mohamed Mohamed, Abdallah Attia, Danielle Tatum, Jamil Borgi, Eman A Toraih

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shriya ChunduriTulane University School of Medicine, New Orleans, LA, USA.
Ghassan BidaouiTulane Research Innovation for Arrhythmia Discovery (TRIAD) Center, Tulane University School of Medicine, New Orleans, LA, USA.
Mohammad H HusseinOchsner Clinic Foundation, New Orleans, LA, USA.
Milee PatelTulane University School of Medicine, New Orleans, LA, USA.
Ahmed AbdelmaksoudDepartment of Internal Medicine, University of California, Riverside, CA, 92521, USA.
Mohamed MohamedDepartment of Internal Medicine, University of California, Riverside, CA, 92521, USA.
Abdallah AttiaDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA, 70112, USA.
Danielle TatumDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA, 70112, USA.
Jamil BorgiDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA, 70112, USA.ORCID 0000-0001-9267-3787
Eman A ToraihDepartment of Cardiovascular Perfusion, College of Health Professions, Upstate Medical University, New York, NY, USA. etoraih@tulane.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the effectiveness of tirzepatide (a dual GLP-1/GIP receptor agonist) versus semaglutide (a GLP-1 receptor agonist) in improving postoperative outcomes among patients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG).

methodsWe conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed. Primary outcomes included cerebrovascular and cardiovascular events, postoperative complications, healthcare utilization, and all-cause mortality, assessed at 6-month and 3-year intervals. P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure.

resultsTirzepatide was associated with significantly lower risks of cerebrovascular events at both follow-up points, including reduced incidence of cerebrovascular disease (11.8% vs. 17.5%; HR = 0.831), cerebral infarction (4.6% vs. 7.3%; HR = 0.788), and cerebral occlusion without infarction (6.8% vs. 10.4%; HR = 0.838)-all of which remained statistically significant after multiple comparison correction (adjusted p = 0.0024). Cardiovascular outcomes also favored tirzepatide, with significant reductions in major adverse cardiovascular events (MACE) (39.7% vs. 49.5%; HR = 0.911), myocardial infarction (7.0% vs. 10.8%; HR = 0.838), and acute coronary disease (1.1% vs 2.3%; HR = 0.691); several of these remained significant after correction at both timepoints. While tirzepatide was associated with lower rates of surgical site infection, venous thrombosis, and CABG-specific complications, only venous thrombosis remained statistically significant after adjustment (adjusted p = 0.021). Additionally, tirzepatide users had reduced healthcare utilization and lower all-cause mortality, with 3-year readmission (16.4% vs. 23.4%; HR = 0.871) and mortality (1.9% vs. 4.7%; HR = 0.595) both remaining significant after adjustment (adjusted p = 0.002). Kaplan-Meier analysis confirmed sustained survival benefit.

conclusionIn patients with T2DM undergoing CABG, tirzepatide was associated with improved cerebrovascular and cardiovascular outcomes, reduced venous thrombotic complications, and lower long-term mortality and healthcare utilization compared to semaglutide. These findings support the therapeutic potential of dual GLP-1/GIP receptor agonism in high-risk post-CABG populations.

Indexed as

Cerebrovascular DisordersCoronary Artery BypassCoronary Artery DiseaseDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsAgedFemaleHumansMaleMiddle AgedPostoperative ComplicationsPropensity ScoreRetrospective StudiesRisk AssessmentGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsTirzepatideCABGCardiovascular outcomesCerebrovascular diseaseGLP-1/GIP receptor agonistMortalitySemaglutideTirzepatideType 2 diabetes

Identifiers

PMID40938549

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.